JPMorgan Chase & Co. initiated coverage on shares of Bausch Health Companies (NYSE:BHC – Get Rating) in a research note issued on Monday, The Fly reports. The firm set an “overweight” rating on the stock.
A number of other research firms also recently issued reports on BHC. TheStreet downgraded Bausch Health Companies from a “c-” rating to a “d+” rating in a research report on Monday, March 28th. Piper Sandler decreased their target price on Bausch Health Companies from $27.00 to $7.00 in a research report on Thursday, May 26th. StockNews.com downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. Royal Bank of Canada reduced their price target on Bausch Health Companies from $21.00 to $17.00 and set an “outperform” rating for the company in a research report on Sunday, May 15th. Finally, Bank of America reduced their price target on Bausch Health Companies from $25.00 to $12.00 in a research report on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $16.40.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
BHC stock opened at $8.03 on Monday. Bausch Health Companies has a twelve month low of $7.80 and a twelve month high of $32.08. The stock’s 50 day moving average is $15.47 and its 200-day moving average is $21.51. The firm has a market capitalization of $2.90 billion, a PE ratio of -7.04, a P/E/G ratio of 0.18 and a beta of 1.66.
Bausch Health Companies (NYSE:BHC – Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The company reported $0.72 EPS for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.31). Bausch Health Companies had a negative net margin of 4.89% and a negative return on equity of 649.29%. The business had revenue of $1.92 billion for the quarter, compared to analysts’ expectations of $2.06 billion. On average, research analysts expect that Bausch Health Companies will post 4.06 EPS for the current year.
In related news, insider Robert Spurr sold 4,846 shares of Bausch Health Companies stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $22.20, for a total transaction of $107,581.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.75% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of BHC. Guardian Capital Advisors LP lifted its stake in Bausch Health Companies by 154.6% during the fourth quarter. Guardian Capital Advisors LP now owns 36,650 shares of the company’s stock worth $992,000 after purchasing an additional 22,255 shares during the last quarter. National Bank of Canada FI bought a new stake in Bausch Health Companies during the fourth quarter worth about $4,525,000. Fifth Third Bancorp lifted its stake in Bausch Health Companies by 296.0% during the fourth quarter. Fifth Third Bancorp now owns 4,348 shares of the company’s stock worth $120,000 after purchasing an additional 3,250 shares during the last quarter. Bridgewater Associates LP lifted its stake in Bausch Health Companies by 69.3% during the fourth quarter. Bridgewater Associates LP now owns 145,245 shares of the company’s stock worth $4,018,000 after purchasing an additional 59,478 shares during the last quarter. Finally, Franklin Resources Inc. lifted its stake in Bausch Health Companies by 11.3% during the third quarter. Franklin Resources Inc. now owns 208,624 shares of the company’s stock worth $5,810,000 after purchasing an additional 21,180 shares during the last quarter. 73.38% of the stock is owned by institutional investors.
Bausch Health Companies Company Profile (Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Bausch Health Companies right now?
Before you consider Bausch Health Companies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Bausch Health Companies wasn’t on the list.
While Bausch Health Companies currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
